This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Zinforo efficacy has been confirmed in cSSTI and CAP patients in a real-world setting

​​​​​​​CAPTURE was a retrospective cohort study relating to current treatment practice in the US. In CAPTURE, 'clinical success' was defined as clinical cure with no further need for antibiotic therapy or clinical improvement with switch to oral agents at end of Zinforo® treatment. As CAPTURE was a retrospective chart review study, it has the limitations inherent to this study design.5,10

CAP: Clinical success in selected subgroups of the CAPTURE study||*2,5​​​​​​​

cSSTI: Clinical success in selected subgroups of the CAPTURE study2-4

Explore More

Discover specific information on the use of Zinforo in neonates, infants and children here:



†Zinforo is suitable for patients with a range of BMIs, and doesn't need to be dosed on a weight basis.4
‡Normal/mild renal insufficiency, or moderate or severe renal insufficiency. Overall clinical success rates were 88–91%.9
||CAPTURE was a retrospective cohort study relating to current treatment practice in the US. In CAPTURE, 'clinical success' was defined as clinical cure with no further need for antibiotic therapy or clinical improvement with switch to oral agents at end of Zinforo® treatment. As CAPTURE is a retrospective chart review study, it has the limitations inherent to this study design.5,10​​​​​​ 
*Shown not to be statistically significant10                                                                                                                          

Abbreviations
​​​​​​​
CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; CAPTURE, Clinical Assessment Program and TEFLARO Utilization Registry; NS, non significant
References
  1. ZINFORO. Summary of Product Characteristics
  2. Maggiore C, et al. Expert Rev Clin Pharmacol 2015;8:141–53
  3. Santos PD, et al. J Chemother 2013;25:341–6
  4. Evans JD, et al. Postgrad Med 2014;126:128–34
  5. Udeani G, et al. Hosp Prac 2014;42:109–15
  6. Laudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18
  7. Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103
  8. Drusano, GL. J Antimicrob Chemother 2011;66(Suppl3):iii61–7
  9. Friedland D, et al. Antimicrob Agents Chemother 2012;56;2231–6
  10. Eckburg P, et al. Infect Dis Clin Pract 2012;20:254–60
PP-ZFO-GBR-0145. June 2021

Tolerability profile of Zinforo

Access data on the safety profile of Zinforo as established in key Phase III clinical trials

View tolerability profile

** This is an optional area where footnotes can live.

Discover more about the risk factors associated with disease severity, comorbidities and resistance in CAP and cSSTI

Patient Risk Factors

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No